CSL Limited (OTCMKTS:CSLLY) Short Interest Up 43.7% in April

CSL Limited (OTCMKTS:CSLLY - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 18,100 shares, a growth of 43.7% from the March 31st total of 12,600 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 304,900 shares, the short-interest ratio is presently 0.1 days.

CSL Stock Performance

OTCMKTS CSLLY traded up $0.40 on Monday, hitting $83.40. 49,683 shares of the company's stock traded hands, compared to its average volume of 94,948. CSL has a 1-year low of $70.22 and a 1-year high of $109.00. The firm's 50-day moving average price is $78.70 and its two-hundred day moving average price is $85.27. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded shares of CSL to a "strong-buy" rating in a research report on Thursday, January 16th.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.